AbbVie · 21 hours ago
Associate Scientist, Process Development I
AbbVie is a company dedicated to discovering and delivering innovative medicines and solutions that address serious health issues. The Associate Scientist, Process Development I role involves generating and analyzing precise data under supervision, following established protocols, and maintaining laboratory operations.
BiotechnologyFinancial ServicesHealth CareMedicalPharmaceuticalVenture Capital
Responsibilities
Completely follow established experimental protocols and assess results with supervision
Recognize and report experimental variances
Apply basic scientific principles to research
Learn and effectively implement new experimental protocols and/or techniques. Maintain laboratory equipment and optimize laboratory operations for efficient use of time and laboratory supplies and reagents, when appropriate
Consult literature to understand scientific purpose of assignments. Impact projects predominantly through lab and/or pilot plant based activities
Understand and adhere to corporate standards regarding code of conduct, safety, appropriate handling of materials, controlled drug and radioactive compounds, GxP compliance, and animal care where applicable
Qualification
Required
Bachelor's Degree, or equivalent education
Theoretical and practical knowledge to carry out job functions
Benefits
Paid time off (vacation, holidays, sick)
Medical/dental/vision insurance
401(k)
Company
AbbVie
AbbVie is a biopharmaceutical company focused on immunology, oncology, neuroscience, virology, and aesthetics. It is a sub-organization of AbbVie.
H1B Sponsorship
AbbVie has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (273)
2024 (190)
2023 (225)
2022 (284)
2021 (186)
2020 (186)
Funding
Current Stage
Public CompanyTotal Funding
$15B2024-02-27Post Ipo Debt· $15B
2023-03-08Post Ipo Equity· $0.25M
2012-12-20IPO
Leadership Team
Recent News
2026-01-09
2026-01-08
Morningstar.com
2026-01-08
Company data provided by crunchbase